<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00558428</url>
  </required_header>
  <id_info>
    <org_study_id>1235.5</org_study_id>
    <secondary_id>EUDRACT2007-002409-36</secondary_id>
    <nct_id>NCT00558428</nct_id>
  </id_info>
  <brief_title>Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension</brief_title>
  <official_title>An Eight-week Randomized, 4-arm, Double-blind Study to Compare the Efficacy and Safety of Combinations of Telmisartan 40mg + Amlodipine 5mg Versus Telmisartan 80mg + Amlodipine 5mg Versus Amlodipine 5mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 5mg Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objectives of this trial are (a) to demonstrate that the fixed-dose combination
      T40/A5 or the fixed-dose combination T80/A5 is superior in reducing blood pressure at eight
      weeks compared with A5 (b) to demonstrate that the fixed-dose combination T40/A5 or the
      fixed-dose combination T80/A5 is not inferior in reducing blood pressure at eight weeks
      compared with A10 and (c) to demonstrate that the incidence of oedema on the fixed-dose
      combination T40/A5 pooled with the fixed-dose combination T80/A5 is superior (less oedema) to
      A10 in patients who fail to respond adequately to six weeks treatment with A5.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP)</measure>
    <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
    <description>Change from baseline to the end of study in trough DBP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Oedema</measure>
    <time_frame>During randomised treatment period (8 weeks was the planned end of treatment, some of the measurements analysed as end of study can be at 4 weeks or at any point on randomised treatment)</time_frame>
    <description>Patients from the treated set who experienced at least one case of general oedema.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated Systolic Blood Pressure (SBP)</measure>
    <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
    <description>Change from baseline to the end of study in trough SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated Diastolic Blood Pressure Control</measure>
    <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target DBP of &lt;90mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated DBP Response</measure>
    <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target DBP of &lt;90mmHg or had a reduction in DBP &gt;= 10mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated SBP Control</measure>
    <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target SBP of &lt;140mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated SBP Response</measure>
    <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach the target SBP of &lt;140mmHg or had a reduction in SBP &gt;= 15 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Seated Blood Pressure (BP) Normality Classes</measure>
    <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
    <description>The number of patients who reach predefined BP categories:
Optimal - SBP&lt;120 and DBP&lt;80 mmHg
Normal - SBP&lt;130 and DBP&lt;85 mmHg
High-normal - SBP&lt;140 DBP&lt;90 mmHg
Stage 1 hypertension - SBP&lt;160 and DBP&lt;100
Stage 2 hypertension SBP&gt;=160 and DBP&gt;=100 mmHg</description>
  </secondary_outcome>
  <enrollment type="Actual">1098</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fixed dose combination of telmisartan+amlodipine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients aged at least 18 years at the date of signing the consent form

          2. diagnosis of essential hypertension and blood pressure not adequately controlled
             before enrolment in the study

          3. failure to respond adequately to six weeks treatment with amlodipine 5 mg monotherapy

          4. able to stop any current antihypertensive therapy without unacceptable risk to the
             patient (Investigator's decision)

          5. willing and able to provide written informed consent (in accordance with Good Clinical
             Practice and local legislation).

        Exclusion Criteria:

          1. are not practising acceptable means of birth control or do not plan to continue using
             acceptable means of birth control throughout the study and do not agree to submit to
             pregnancy testing during participation in the trial. Acceptable methods of birth
             control include the transdermal patch, oral, implantable or injectable contraceptives,
             sexual abstinence and vasectomised partner.

          2. known or suspected secondary hypertension

          3. mean seated systolic blood pressure (SBP) over 200 mmHg and/or mean seated diastolic
             blood pressure (DBP) over 120 mmHg at Visit 1 or 2 or mean seated SBP over 180 mmHg
             and/or mean seated DBP over 120 mmHg at the end of the run-in period (Visit 3)

          4. any clinically significant hepatic impairment (e.g. clinically significant
             cholestasis, biliary obstructive disorder or hepatic insufficiency)

          5. severe renal impairment (e.g. serum creatinine &gt;3.0 mg/dL or &gt;265 mcmol/L, known
             creatinine clearance &lt;30mL/min or clinical markers of severe renal impairment)

          6. bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or
             post-renal transplant

          7. clinically relevant hyperkalaemia

          8. uncorrected volume or sodium depletion.

          9. primary aldosteronism.

         10. hereditary fructose or lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.5.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aywaille</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.32010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goz√©e</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.32008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linkebeek</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mol</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.32007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Natoye</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.32009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tavier</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tienen-Kumtich</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.20001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.20011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.20007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.20005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.20008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.20013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corunna</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.20014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.20010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.20012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.20009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.20006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.20003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birker√∏d</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.45005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haderslev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.45008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Herning</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.45009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hinnerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>R√∏dovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.45006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>R√∏dovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vaerl√∏se</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.45007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vildbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.35003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.35004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.35001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.35002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3301H Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aigrefeuille S/Maine</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3306C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3309B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3309C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3309E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3309D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Avrille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3309A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beaucouze</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourg des cptes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3306D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Briollay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3308B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3308C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3308D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3308F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3302C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Garchizy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3303C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Grandchamps</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3302D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guerigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3310A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jarny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3301L Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Chapelle /s Erdre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3301J Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Chapelle sur Erdre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Fresnais</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3308E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Jubaudi√®re</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3301G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Montagne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3303B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Bono</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3307D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Mesnil en Vall√©e</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3301E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Temple de Bretagne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3309F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Les Ponts de CE</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3307G Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Loudun</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3305B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louvign√© le Bais</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3307E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mouliherne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Murs Erigne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Murs-Erigne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3301B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3301D Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3301M Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nevers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3302F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nevers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3301I Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nort sur Erdre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3301C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orvault</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3307F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Parcay les Pins</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3307C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Pierre Montlimard</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3301N Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sautron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3306B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Segre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3301F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Aubin les Ch√¢teaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3306F Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Georges de Montaigu</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3304B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Ouen La Rouerie</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3306E Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thouars</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3304C Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tint√©niac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vannes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vihiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daejon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gangwon-Do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.31008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beerzerveld</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bennebroek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoogwoud</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Musselkanaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.31007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nijverdal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oude Pekela</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roelofarendsveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.31010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Voerendaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.47003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.47004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>√Ölesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.63006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.63001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.63002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.63009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.63008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pasay City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.63005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pasig City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.63003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.63007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boksburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.27009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.27010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.27004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.27008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.27005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lenasia</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>G√∂teborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>G√∂teborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lule√•</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>R√§ttvik</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.88605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.88608 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hualien City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.88601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.5.88603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2007</study_first_posted>
  <results_first_submitted>November 13, 2009</results_first_submitted>
  <results_first_submitted_qc>November 13, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 15, 2009</results_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1487 were enrolled, 1098 entered but 1 patient not treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Amlodipine 5mg</title>
        </group>
        <group group_id="P2">
          <title>Amlodipine 10mg</title>
        </group>
        <group group_id="P3">
          <title>Telmisartan 40mg and Amlodipine 5mg</title>
        </group>
        <group group_id="P4">
          <title>Telmisartan 80mg and Amlodipine 5mg</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="267"/>
                <participants group_id="P2" count="276"/>
                <participants group_id="P3" count="277"/>
                <participants group_id="P4" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
                <participants group_id="P2" count="252"/>
                <participants group_id="P3" count="273"/>
                <participants group_id="P4" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amlodipine 5mg</title>
        </group>
        <group group_id="B2">
          <title>Amlodipine 10mg</title>
        </group>
        <group group_id="B3">
          <title>Telmisartan 40mg and Amlodipine 5mg</title>
        </group>
        <group group_id="B4">
          <title>Telmisartan 80mg and Amlodipine 5mg</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="267"/>
            <count group_id="B2" value="276"/>
            <count group_id="B3" value="277"/>
            <count group_id="B4" value="277"/>
            <count group_id="B5" value="1097"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="10.6"/>
                    <measurement group_id="B2" value="54.3" spread="10.6"/>
                    <measurement group_id="B3" value="53.9" spread="11"/>
                    <measurement group_id="B4" value="54.5" spread="10.2"/>
                    <measurement group_id="B5" value="54.2" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="94"/>
                    <measurement group_id="B5" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="160"/>
                    <measurement group_id="B4" value="183"/>
                    <measurement group_id="B5" value="682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP)</title>
        <description>Change from baseline to the end of study in trough DBP</description>
        <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP)</title>
          <description>Change from baseline to the end of study in trough DBP</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="270"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.71" spread="0.49"/>
                    <measurement group_id="O2" value="-7.95" spread="0.49"/>
                    <measurement group_id="O3" value="-9.35" spread="0.48"/>
                    <measurement group_id="O4" value="-10.63" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline and country effect</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-3.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.90</ci_lower_limit>
            <ci_upper_limit>-2.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline and country effect</method_desc>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-4.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.18</ci_lower_limit>
            <ci_upper_limit>-3.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.66</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.93</ci_lower_limit>
            <ci_upper_limit>-1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated Systolic Blood Pressure (SBP)</title>
        <description>Change from baseline to the end of study in trough SBP</description>
        <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated Systolic Blood Pressure (SBP)</title>
          <description>Change from baseline to the end of study in trough SBP</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="270"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.18" spread="0.73"/>
                    <measurement group_id="O2" value="-11.11" spread="0.72"/>
                    <measurement group_id="O3" value="-13.56" spread="0.71"/>
                    <measurement group_id="O4" value="-14.99" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated Diastolic Blood Pressure Control</title>
        <description>The number of patients who reach the target DBP of &lt;90mmHg</description>
        <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated Diastolic Blood Pressure Control</title>
          <description>The number of patients who reach the target DBP of &lt;90mmHg</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="270"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (DBP&lt;90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="148"/>
                    <measurement group_id="O3" value="153"/>
                    <measurement group_id="O4" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (DBP&gt;=90 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="113"/>
                    <measurement group_id="O3" value="117"/>
                    <measurement group_id="O4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated DBP Response</title>
        <description>The number of patients who reach the target DBP of &lt;90mmHg or had a reduction in DBP &gt;= 10mmHg</description>
        <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated DBP Response</title>
          <description>The number of patients who reach the target DBP of &lt;90mmHg or had a reduction in DBP &gt;= 10mmHg</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="270"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (Responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="177"/>
                    <measurement group_id="O4" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (Non-responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated SBP Control</title>
        <description>The number of patients who reach the target SBP of &lt;140mmHg</description>
        <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated SBP Control</title>
          <description>The number of patients who reach the target SBP of &lt;140mmHg</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="270"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (SBP&lt;140 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="162"/>
                    <measurement group_id="O4" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (SBP&gt;=140 mmHg)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="108"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated SBP Response</title>
        <description>The number of patients who reach the target SBP of &lt;140mmHg or had a reduction in SBP &gt;= 15 mmHg</description>
        <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated SBP Response</title>
          <description>The number of patients who reach the target SBP of &lt;140mmHg or had a reduction in SBP &gt;= 15 mmHg</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="270"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes (Responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="166"/>
                    <measurement group_id="O3" value="187"/>
                    <measurement group_id="O4" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No (Non-responder)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Seated Blood Pressure (BP) Normality Classes</title>
        <description>The number of patients who reach predefined BP categories:
Optimal - SBP&lt;120 and DBP&lt;80 mmHg
Normal - SBP&lt;130 and DBP&lt;85 mmHg
High-normal - SBP&lt;140 DBP&lt;90 mmHg
Stage 1 hypertension - SBP&lt;160 and DBP&lt;100
Stage 2 hypertension SBP&gt;=160 and DBP&gt;=100 mmHg</description>
        <time_frame>End of study (8 weeks or last value on treatment)</time_frame>
        <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>Trough Seated Blood Pressure (BP) Normality Classes</title>
          <description>The number of patients who reach predefined BP categories:
Optimal - SBP&lt;120 and DBP&lt;80 mmHg
Normal - SBP&lt;130 and DBP&lt;85 mmHg
High-normal - SBP&lt;140 DBP&lt;90 mmHg
Stage 1 hypertension - SBP&lt;160 and DBP&lt;100
Stage 2 hypertension SBP&gt;=160 and DBP&gt;=100 mmHg</description>
          <population>Full analysis set of patients who had a baseline trough blood pressure measurement and at least one post baseline trough blood pressure measurement using last observation carried forward. The full analysis set included patients who had baseline and at least one post baseline trough measure of blood pressure</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="270"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 1 hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="127"/>
                    <measurement group_id="O4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage 2 hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Oedema</title>
        <description>Patients from the treated set who experienced at least one case of general oedema.</description>
        <time_frame>During randomised treatment period (8 weeks was the planned end of treatment, some of the measurements analysed as end of study can be at 4 weeks or at any point on randomised treatment)</time_frame>
        <population>The treated set (TS) consisted of all patients that took at least one dose of the double-blind treatment (n=1097)</population>
        <group_list>
          <group group_id="O1">
            <title>Amlodipine 5mg</title>
          </group>
          <group group_id="O2">
            <title>Amlodipine 10mg</title>
          </group>
          <group group_id="O3">
            <title>Telmisartan 40mg and Amlodipine 5mg</title>
          </group>
          <group group_id="O4">
            <title>Telmisartan 80mg and Amlodipine 5mg</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Oedema</title>
          <description>Patients from the treated set who experienced at least one case of general oedema.</description>
          <population>The treated set (TS) consisted of all patients that took at least one dose of the double-blind treatment (n=1097)</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="261"/>
                <count group_id="O3" value="270"/>
                <count group_id="O4" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with any oedema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients with general oedema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From day of first dose until one day after last dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Amlodipine 5mg</title>
        </group>
        <group group_id="E2">
          <title>Amlodipine 10mg</title>
        </group>
        <group group_id="E3">
          <title>Telmisartan 40mg and Amlodipine 5mg</title>
        </group>
        <group group_id="E4">
          <title>Telmisartan 80mg and Amlodipine 5mg</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="267"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

